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Abstract
Background: Assuming a higher risk of latent tuberculosis (TB) infection in the population of Rio de Janeiro,
Brazil, in October of 1998 the TB Control Program of Clementino Fraga Filho Hospital (CFFH) routinely started
to recommend a two-step tuberculin skin test (TST) in contacts of pulmonary TB cases in order to distinguish a
boosting reaction due to a recall of delayed hypersensitivity previously established by infection with Mycobacterium
tuberculosis (M.tb) or BCG vaccination from a tuberculin conversion. The aim of this study was to assess the
prevalence of boosted tuberculin skin tests among contacts of individuals with active pulmonary tuberculosis (TB).
Methods: Retrospective cohort of TB contacts ≥ 12 years old who were evaluated between October 1st, 1998
and October 31st 2001. Contacts with an initial TST ≤ 4 mm were considered negative and had a second TST
applied after 7–14 days. Boosting reaction was defined as a second TST ≥ 10 mm with an increase in induration
≥ 6 mm related to the first TST. All contacts with either a positive initial or repeat TST had a chest x-ray to rule
out active TB disease, and initially positive contacts were offered isoniazid preventive therapy. Contacts that
boosted did not receive treatment for latent TB infection and were followed for 24 months to monitor the
development of TB. Statistical analysis of dichotomous variables was performed using Chi-square test. Differences
were considered significant at a p < 0.05.
Results: Fifty four percent (572/1060) of contacts had an initial negative TST and 79% of them (455/572) had a
second TST. Boosting was identified in 6% (28/455). The mean age of contacts with a boosting reaction was 42.3
± 21.1 and with no boosting was 28.7 ± 21.7 (p = 0.01). Fifty percent (14/28) of individuals whose test boosted
met criteria for TST conversion on the second TST (increase in induration ≥ 10 mm). None of the 28 contacts
whose reaction boosted developed TB disease within two years following the TST.
Conclusion: The low number of contacts with boosting and the difficulty in distinguishing boosting from TST
conversion in the second TST suggests that the strategy of two-step TST testing among contacts of active TB
cases may not be useful. However, this conclusion must be taken with caution because of the small number of
subjects followed.
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Background
The tuberculin skin test (TST) is used to determine if a per-
son has been infected by Mycobacterium tuberculosis [1].
However, response to M. tuberculosis antigens may wane
over time in an individual with latent tuberculosis (TB)
infection or who is exposed to nontuberculous mycobac-
teria, including BCG vaccine. Re-exposure with tuberculin
may result in an anamnestic-like response of the cellular
immune system, resulting in a subsequent positive reac-
tion on repeated skin testing. The use of serial TSTs to
detect new instances of infection among high risk popula-
tions such as healthcare workers or contacts of pulmonary
TB cases with negative TST in the initial evaluation has
presented a new question: is an increase in the second
tuberculin reaction size due to a recall of delayed hyper-
sensitivity previously established by infection with Myco-
bacterium tuberculosis (M.tb) or BCG vaccination that has
waned over the years or due to a new M.tb infection (con-
version) [2]? Because of this issue, some centers with a
high prevalence of TB utilize a two-step TST with a second
tuberculin test being performed between 1 and 5 weeks
after the first test [3,4]. Assuming a higher risk of latent TB
infection in the general population of the city of Rio de
Janeiro, with a TB incidence rate of 114/100,000 [5], in
October 1998 the TB Control Program of Clementino
Fraga Filho University Hospital (CFFH) of the Federal
University of Rio de Janeiro (FURJ), Brazil, routinely
started to recommend a two-step TST in contacts of pul-
monary TB cases.
The purpose of this study was to assess the prevalence of
boosted tuberculin skin test among contacts of individu-
als with active pulmonary TB and the importance of this
strategy for a TB Control Program in a setting with a high
prevalence of TB.
Methods
All charts of TB contacts evaluated between October 1st,
1998 and October 31st 2001 were retrospectively reviewed
by trained staff. Contacts with two-step TST (test 1 and test
2) and chest X-ray results described in the chart were
enrolled in the study and had data recorded.
Contacts of culture positive TB cases are routinely evalu-
ated 4–6 weeks after the start of the anti-TB treatment of
the index case (using the Brazilian Ministry of Health rec-
ommended regimen of isoniazid, rifampin and pyrazina-
mide). The evaluation of household contacts was
performed by the TB Control Program staff and included
a two-step TST and a chest X-ray. The TST was applied to
the forearm using the Mantoux technique and was read by
health care workers trained and certificated (degree of
intra-reader reliability > 95% and inter-reader reliability ≥
80%). All testing was performed using purified protein
derivative (PPD), RT23 (0.1 ml = 2 TU) (Staten Serum
Institute, Copenhagen, Denmark). The initial TST (test 1)
was read 2–3 days after application. Contacts with a read-
ing on the first TST (test 1) of ≤ 4 mm induration were
classified as negative [6] and were asked to return for a sec-
ond TST (test 2) applied 1–2 weeks after test 1. Boosting
reaction was defined as having a reaction of ≥ 10 mm on
test 2, with an increase in induration of at least 6 mm
related to test 1 [7,8]. Contacts without boosting were
submitted to a third TST (test 3) 12 weeks after the first
evaluation to evaluate TST conversion [6]. Boosting sub-
jects (as evaluated at test 2) did not receive treatment for
latent tuberculosis infection (TBLI) and were followed-up
for at least 24 months to determine their TB status.
The study was approved by the Ethic Committee of Fed-
eral University of Rio de Janeiro (Brazil).
Statistical analysis of continuous variables was performed
using Student's t-test and of dichotomous variables using
Chi-square test. Differences were considered significant at
a p < 0.05. The analysis was performed using SPSS Version
11.0.
Results
The study population was comprised of 1,191 identified
contacts of 283 culture positive pulmonary TB index
cases. In 89% (1060/1191) of these contacts an initial TST
was performed and read. Figure 1 presents the flow of the
study. Among 54% (572/106) of contacts with a negative
initial TST (TST ≤ 4 mm), 455 had a second TST applied
and read 1–2 weeks after the first test and the criteria for a
"booster" phenomenon was met in 6% (28/455). Fifty
percent (14/28) of contacts identified as boosting had an
increase of the induration size of at least 10 mm in the sec-
ond TST. In table 1 the characteristics of contacts are pre-
sented. The mean age of contacts with a "booster"
phenomenon (42.3 years; ± 21.1) was higher than con-
Table 1: Characteristics of 455 contacts according with the presence of boosting
Presence of boosting Absence of boosting P value
Gender (male/female) 9/19 151/276 0.8
Presence of BCG scar* (yes/no) 16/11 293/127 0.2
Age (mean ± SD) 42.3 ± 21.1 28.7 ± 21.7 0,001
SD: standard deviation; * There was information about BCG vaccination in the chart of 447 contacts that underwent the second TST.
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tacts with no "booster" phenomenon (28.7 years; ± 21.7;
p = 0.001). Only 14% (4/28) of contacts were tested for
HIV and all were negative. Nine percent (11/127) of con-
tacts with no BCG scar demonstrated "booster" phenom-
enon compared to 5% (16/296) with BCG scar (p = 0.2).
None of the 28 contacts defined by the TB Control Pro-
gram as having a "booster" phenomenon developed TB
disease within two years after the TST.
Discussion
Six percent (28 subjects) of 455 initially negative contacts
≥ 12 years old who had a second TST applied and read
within 2 weeks after the first test boosted on retesting and
none developed active TB in 2 years of follow up.
Some North America guidelines, propose treatment with
isoniazid for contacts of smear positive pulmonary TB
Prevalence of boosting among contacts of active pulmonary tuberculosis casesFigur  1
Prevalence of boosting among contacts of active pulmonary tuberculosis cases.
1191 close contacts
TST 4 mm 
N = 572 
TST  5 mm 
N = 488 
Lost = 131
Second TST (7-14 days after the first one)
                
N = 455 
Presence of boosting
N = 28 
Lost = 117 
Absence of boosting
N = 427 
N = 1060
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with a TST ≥ 5 mm as well as for those with a tuberculin
conversion demonstrated as an increase of 10 mm in the
induration size of a second tuberculin test within a two
year period [1,6].
The prevalence of boosting is generally correlated with the
prevalence of the initial positive tuberculin reactions [2].
Gordin et al (1988) evaluated a large group of people in
several chronic care facilities and found an initial rate of
positive tests in 28% (477/1728) of the subjects and a
boosting rate of 14% (158/1146). Since 46% (488/1060)
of contacts in the present study were TST positive, a boost-
ing rate higher than 6% would be expected. The finding in
our sample is similar to a study performed among stu-
dents in Canada that found a boosting rate of 5.2% (74/
1435), however in that study the initial TST rate was 6.6%
[9]. Vaccination with BCG among children less than one
year of age has been obligatory in Brazil since 1976 and
compliance with this policy is assumed high. The presence
of BCG scar apparently did not have any influence on the
incidence of a "booster" phenomenon in this series of
contacts. The mean age of the subjects (28.8 years old)
evaluated in this study means that BCG vaccination
occurred more than 10 years before the TST may justify
this finding [9].
In the TB Control Program of CFFH/FURJ the first TST of
contacts is routinely done 4–6 weeks after the index case
starts TB treatment and a second TST (when indicated) is
done 1–2 weeks after the first test. In the current study,
50% of contacts who met criteria for "booster" phenome-
non in the second TST had an increase ≥ 10 mm of indu-
ration size, which is both the Brazilian and the widely
recognized criterion for identifying a tuberculin conver-
sion case [1,2,6]. As there is a significant decrease in the
infectiousness of pulmonary TB in the index case after
starting anti-TB drugs, patients can generally be assumed
as noninfectious to contacts after 2–4 weeks of treatment
[10]. The period of time between the decrease in the infec-
tiousness of the index case and the placement of the sec-
ond TST, as well as the documented risk of infection
among contacts of active TB cases makes it difficult to dis-
tinguish which contact is boosting and which one is a
recent tuberculin conversion (recent infection) [11]. Two
different studies have shown that among TST converters
the risk for developing active TB in the first year of follow
up was 8 times higher than in the subsequent seven years
and that 82% of TB cases developed active disease within
2 years of infection [4,6]. None of the 28 subjects catego-
rized as boosters in this study developed active TB within
the two year follow-up period. However, the small sample
size does not allow for a conclusion as to whether these
subjects represented boosting phenomena instead of
recent conversion, even though it is not enough to defini-
tively undermine importance of two step TST strategy in a
different clinical context. The low number of contacts of
active TB cases with boosting identified over three years
(6%), the cost and the time consuming beyond the diffi-
culty in distinguishing boosting from TST conversion in
the second TST suggests that the strategy of two-step TST
specifically among contacts of active pulmonary TB cases
for identify boosting subjects may not be worthwhile. This
conclusion must be taken with caution because the small
number of subjects followed.
Conclusion
The low number of contacts with boosting and the diffi-
culty in distinguishing boosting from TST conversion in
the second TST suggests that the strategy of two-step TST
testing among contacts of active TB cases may be not
worthwhile. However, this conclusion must be taken with
caution because the small number of subjects followed.
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